Study Title: A Phase II Study Evaluating Safety and Efficacy of Durvalumab (MEDI4736) Following Multi-modality Therapy in Esophageal Cancer: Big Ten Cancer Research Consortium BTCRC-ESO14-012
 

• Status: Completed

• Participating Institutions:  
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center
  • Holden Comprehensive Cancer Center, University of Iowa
  • University of Michigan Rogel Cancer Center
• Learn more:
  • clinicaltrials.gov: NCT02639065
  • Big Ten CRC News Release
• Publications and Presentations:
  • Poster: 2020 ASCO Annual Meeting
  • Poster Session: 2020 Gastrointestinal Cancers Symposium
  • Poster Session: 2019 ASCO Annual Meeting
  • Rapid Abstract Session: 2019 Gastrointestinal Cancers Symposium
  • Publication Only: 2018 ASCO Annual Meeting
  • Trials in Progress Poster Session: 2018 Gastrointestinal Cancers Symposium